18:55 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Zynerba refocusing on CBD gel following failed patch readout

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will focus on developing ZYN002 after single and multiple doses of several formulations of ZYN001 failed to achieve target blood levels of 5-15 ng/mL of tetrahydrocannabinol (THC) in a...
18:49 , Jul 5, 2018 |  BC Extra  |  Clinical News

Zynerba refocusing on CBD gel following failed patch readout

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will focus on developing ZYN002 after single and multiple doses of several formulations of ZYN001 failed to achieve target blood levels of 5-15 ng/mL of tetrahydrocannabinol (THC) in a...
14:55 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

FDA approves GW’s Epidiolex, first marijuana-derived drug

FDA approved Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH) on June 25, marking the first U.S. approval of a marijuana-derived purified substance, according to the agency. Epidiolex is indicated to treat seizures associated with Lennox-Gastaut...
22:02 , Jun 25, 2018 |  BC Extra  |  Company News

FDA approves GW’s Epidiolex, first marijuana-derived drug

FDA approved Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH), marking the first U.S. approval of a marijuana-derived purified substance, according to the agency. Epidiolex is indicated to treat seizures associated with Lennox-Gastaut syndrome and Dravet...
22:09 , Jan 5, 2018 |  BC Week In Review  |  Company News

Zynerba discontinuing ZYN002 and ZYN001 for pain indications

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will discontinue development of ZYN002 to treat osteoarthritis (OA) pain and ZYN001 to treat fibromyalgia and general peripheral neuropathic pain to focus on rare and near-rare neurological and psychiatric...
22:09 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Zynerba reports additional data for epilepsy candidate ZYN002

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) reported data from 171 patients with confirmed refractory epilepsy with focal seizures with or without secondary generalization who completed the Phase II STAR 1 trial and were enrolled in the STAR...
23:08 , Sep 29, 2017 |  BC Extra  |  Clinical News

Zogenix soars on Phase III data for Dravet syndrome candidate

Zogenix Inc. (NASDAQ:ZGNX) rocketed $22.17 (172%) to $35.05 on Friday, adding $550 million in market cap, after reporting that ZX008 as adjunctive therapy met the primary endpoint in the Phase III Study 1 to treat...
21:37 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

Zynerba's ZYN002 meets in Phase II for fragile X

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) reported top-line data from the open-label Phase II FAB-C trial in 20 children ages 6-17 with fragile X syndrome showing that ZYN002 met the primary endpoint of reducing Anxiety, Depression and...
20:51 , Sep 28, 2017 |  BC Extra  |  Clinical News

Zynerba gains on fragile X syndrome data

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) jumped $3.25 (53%) to $9.44 on Thursday after reporting that its synthetic cannabidiol (CBD) gel ZYN002 met the primary endpoint in the open-label Phase II FAB-C trial to treat children with...
19:49 , Aug 18, 2017 |  BC Week In Review  |  Clinical News

Zynerba's ZYN002 misses in Phase II for OA

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) reported top-line data from the Phase II STOP trial in 320 patients with osteoarthritis (OA) of the knee showing that once-daily 250 and 500 mg doses of ZYN002 each missed the...